Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Advanced Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT05498064
What this trial is testing

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Peking Union Medical College Hospital 490
Testing effectiveness (Phase 2)Looking for participantsNCT05713006
What this trial is testing

Alectinib Pharmacokinetic in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIIBALK Gene Mutation
Instituto Nacional de Cancerologia de Mexico 45
Testing effectiveness (Phase 2)Ended earlyNCT02374489
What this trial is testing

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma
National Health Research Institutes, Taiwan 9
Not applicableLooking for participantsNCT06361589
What this trial is testing

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Who this might be right for
ALK-positive Non-small Cell Lung CancerReal World Study
Sichuan Cancer Hospital and Research Institute 200
Large-scale testing (Phase 3)Study completedNCT02075840
What this trial is testing

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Large-scale testing (Phase 3)Study completedNCT01828112
What this trial is testing

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 231
Not applicableActive Not RecruitingNCT07567352
What this trial is testing

Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Who this might be right for
Non-Small-Cell LungALK-positive Advanced NSCLCALK-positive Non-small-cell Lung Cancer+1 more
Pfizer 200
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Large-scale testing (Phase 3)Looking for participantsNCT06765109
What this trial is testing

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc. 450
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Early research (Phase 1)Study completedNCT03420742
What this trial is testing

Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Who this might be right for
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
Takeda 24
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Testing effectiveness (Phase 2)Study completedNCT01625234
What this trial is testing

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Xcovery Holdings, Inc. 131
Early research (Phase 1)Ended earlyNCT02511184
What this trial is testing

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Who this might be right for
ALK-positive Advanced NSCLC
Pfizer 9
Next Page